Research progress of Pomalidomide in the treatment of relapsed/refractory multiple myeloma
-
摘要: 多发性骨髓瘤是一类恶性浆细胞克隆性疾病，是血液系统中第二大常见恶性肿瘤，目前仍不能完全治愈。随着治疗药物的更新换代，近年来患者用药后的反应率和生存率都有了显著提升。但大多数多发性骨髓瘤患者在通过多线方案治疗后反应的深度和持续时间都会降低，导致疾病的侵袭性和耐药性逐渐增加。因此对于复发/难治性多发性骨髓瘤患者，寻求新的药物及新的治疗方案来改善患者的预后至关重要。随着相关研究的深入，以第三代免疫调节剂泊马度胺为代表的联合化疗方案在对标准方案治疗后产生耐药及难治性多发性骨髓瘤的治疗中取得了一定的成效。本文就泊马度胺在治疗复发/难治性多发性骨髓瘤中的最新研究进展作一综述。Abstract: Multiple myeloma(MM) is a kind of malignant plasma cell clonal disease, and it is the second most common malignant tumor of the hematopoietic system which is still not completely cured. With the advent of therapeutic drugs, the response rate and survival rate of MM patients have significantly improved in recent years. However, the depth and duration of response in most MM patients after multi-line therapy is significantly reduced with increased invasiveness and drug resistance. Therefore, it is essential to seek new therapeutic drugs and new approaches for recurrent/refractory MM to improve their prognosis. With the deepening of related research, the combined chemotherapy regimen based on the third-generation immunomodulatory drug Pomalidomide has achieved good results in the treatment of recurrent/refractory MM patients after the treatment of standard regimen. This paper reviews the latest research progress of Pomalidomide in the treatment of recurrent/refractory MM.
-
Key words:
- Pomalidomide /
- relapsed and refractory /
- multiple myeloma /
- immunomodulatory drugs
-
-
[1] Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient[J]. Hematology Am Soc Hematol Educ Program, 2017, 2017(1): 498-507. doi: 10.1182/asheducation-2017.1.498
[2] Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy[J]. Semin Oncol, 2016, 43(6): 676-681. doi: 10.1053/j.seminoncol.2016.11.004
[3] Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide[J]. Blood, 2011, 118: 4771-4779.
[4] Holstein SA, McCarthy PL. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience[J]. Drugs, 2017, 77(5): 505-520. doi: 10.1007/s40265-017-0689-1
[5] Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma[J]. Leuk Lymphoma, 2013, 54(4): 683-687. doi: 10.3109/10428194.2012.728597
[6] Abe Y, Ishida T. Immunomodulatory drugs in the treatment of multiple myeloma[J]. Jpn J Clin Oncol, 2019, 49(8): 695-702. doi: 10.1093/jjco/hyz083
[7] Terpos E, Kanellias N, Christoulas D, et al. Pharmacologic and pharmacokinetic properties of pomalidomide[J]. Onco Targets Ther, 2013, 6: 531-538.
[8] Ito T, Handa H. Molecular mechanisms of thalidomide and its derivatives[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2020, 96(6): 189-203. doi: 10.2183/pjab.96.016
[9] Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide[J]. Leukemia, 2012, 26(11): 2326-2335. doi: 10.1038/leu.2012.119
[10] 樊文静, 范枝俏, 潘耀柱, 等. 泊马度胺的抗骨髓瘤细胞株MM1. S活性及对CRBN表达的影响[J]. 中国实验血液学杂志, 2019, 27(6): 1907-1911. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201906036.htm
[11] Keifer JA, Guttridge DC, Ashburner BP, et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity[J]. Biol Chem, 2001, 276: 22382-22387. doi: 10.1074/jbc.M100938200
[12] Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs(IMiDS)in multiple myeloma[J]. Leukemia, 2010, 24(1): 22-32. doi: 10.1038/leu.2009.236
[13] Bjorklund CC, Lu L, Kang J, et al. Rate of CRL4(CRBN)substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4[J]. Blood Cancer J, 2015, 5: e354. doi: 10.1038/bcj.2015.66
[14] Pan B, Lentzsch S. The application and biology of immunomodulatory drugs(IMiDs)in cancer[J]. Pharmacol Ther, 2012, 136(1): 56-68. doi: 10.1016/j.pharmthera.2012.07.004
[15] Endo S, Amano M, Nishimura N, et al. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU. 1 up-regulation in myeloma cells[J]. Biochem Biophys Res Commun, 2016, 469(2): 236-242. doi: 10.1016/j.bbrc.2015.11.116
[16] Ruchelman AL, Man HW, Zhang W, et al. Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity[J]. Bioorg Med Chem Lett, 2013, 23(1): 360-365. doi: 10.1016/j.bmcl.2012.10.071
[17] Tai YT, Acharya C, An G, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment[J]. Blood, 2016, 127(25): 3225-3236. doi: 10.1182/blood-2016-01-691162
[18] Vo MC, Yang S, Jung SH, et al. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model[J]. Front Immunol, 2018, 9: 1798. doi: 10.3389/fimmu.2018.01798
[19] Giannopoulos K, Kaminska W, Hus I, et al. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma[J]. Br J Cancer, 2012, 106(3): 546-552. doi: 10.1038/bjc.2011.575
[20] Sheng Z, Liu G. Pooled analysis of the reports of pomalidomide after failure of lenalidomide and(or)bortezomib for multiple myeloma[J]. Hematol Oncol, 2016, 34(2): 102-107. doi: 10.1002/hon.2192
[21] Zou Y, Ma X, Yu H, et al. Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials[J]. Oncotarget, 2017, 8(24): 39805-39817. doi: 10.18632/oncotarget.10768
[22] Pusic I, DiPersio JF, Goran SL, et al. Pomalidomide(POM)in advanced corticosteroid-resistant chronic graft-versus-host disease(cGVHD)[J]. Biol Blood Marrow Transpl, 2010, 16(2Suppl 2): S311.
[23] Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study[J]. Blood, 2014, 123(12): 1826-1832. doi: 10.1182/blood-2013-11-538835
[24] Leleu X, Attal M, Arnulf B, et all. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02[J]. Blood, 2013, 121(11): 1968-1975. doi: 10.1182/blood-2012-09-452375
[25] Moreau P, Weisel KC, Song KW, et al. Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase Ⅲ trial[J]. Leuk Lymphoma, 2016, 57(12): 2839-2847. doi: 10.1080/10428194.2016.1180685
[26] Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma(APOLLO): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2021, 22(6): 801-812. doi: 10.1016/S1470-2045(21)00128-5
[27] Baz RC, Martin TG 3rd, Lin HY, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma[J]. Blood, 2016, 127(21): 2561-2568. doi: 10.1182/blood-2015-11-682518
[28] Soekojo CY, Kim K, Huang SY, et al. Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma(AMN001)-a trial by the Asian Myeloma Network[J]. Blood Cancer, 2019, 9(10): 83. doi: 10.1038/s41408-019-0245-1
[29] 李昕, 侯健. 单克隆抗体治疗多发性骨髓瘤新进展[J]. 临床血液学杂志, 2020, 33(7): 451-455. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ202007003.htm
[30] Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide[J]. Leukemia, 2016, 30(2): 399-408. doi: 10.1038/leu.2015.240
[31] San Miguel JF, Weisel KC, Song KW, et al. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma[J]. Haematologica, 2015, 100(10): 1334-1339. doi: 10.3324/haematol.2015.125864
[32] Attal M, Richardson PG, Rajkumar SV, et al. ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma(ICARIA-MM): a randomised, multicentre, open-label, phase 3 study[J]. Lancet, 2019, 394(10214): 2096-2107. doi: 10.1016/S0140-6736(19)32556-5
[33] 郭怀鹏, 康蕾, 刘聪, 等. Daratumumab在新诊断不适合移植及复发难治多发性骨髓瘤治疗的Meta分析[J]. 临床血液学杂志, 2021, 34(11): 795-801, 806. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ202111010.htm
[34] Chari A, Suvannasankha A, Fay JW. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma[J]. Blood, 2017, 130(8): 974-981. doi: 10.1182/blood-2017-05-785246
[35] Mushtaq A, Iftikhar A, Hassan H, et al. Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials[J]. Clin Lymphoma Myeloma Leuk, 2019, 19(7): 447-461. doi: 10.1016/j.clml.2019.04.003
-
计量
- 文章访问数: 1334
- PDF下载数: 1025
- 施引文献: 0
下载: